Attributes | Values |
---|
rdf:type
| |
Description
| - Gemcitabine/cisplatin is among the most widely used regimens inEurope for first-line treatment of non-small cell lung cancer (NSCLC). Problems with cisplatin use in this setting include significant nonhematologie toxicity and difficulty of use in outpatiCarboplatin constitutes a reasonable alternative to cisplatin in this combination, since it showa synergy with gemcitabine in vitro, is easier to use in ambulatory patients, and has a better nonhematolgic toxicity profile. Studies of gemcitabine/cisplation a 28-day shedule (e.g. gemcitabine on days 1, 8, 15 and carboplatin on day 1)generally indicate excessive thrompocytopenia. Use of 21 day shedule (e.g. gemcitabine on days 1 and 8, carboplatin on day 1) is associated with reduced toxicity andcomparable efficiacy.
- Gemcitabine/cisplatin is among the most widely used regimens inEurope for first-line treatment of non-small cell lung cancer (NSCLC). Problems with cisplatin use in this setting include significant nonhematologie toxicity and difficulty of use in outpatiCarboplatin constitutes a reasonable alternative to cisplatin in this combination, since it showa synergy with gemcitabine in vitro, is easier to use in ambulatory patients, and has a better nonhematolgic toxicity profile. Studies of gemcitabine/cisplation a 28-day shedule (e.g. gemcitabine on days 1, 8, 15 and carboplatin on day 1)generally indicate excessive thrompocytopenia. Use of 21 day shedule (e.g. gemcitabine on days 1 and 8, carboplatin on day 1) is associated with reduced toxicity andcomparable efficiacy. (en)
|
Title
| - Gemcitabine/carboplatin in advanced non-small cell lung cancer
- Gemcitabine/carboplatin in advanced non-small cell lung cancer (en)
|
skos:prefLabel
| - Gemcitabine/carboplatin in advanced non-small cell lung cancer
- Gemcitabine/carboplatin in advanced non-small cell lung cancer (en)
|
skos:notation
| - RIV/00023841:_____/02:00005571!RIV/2003/MZ0/L18003/N
|
http://linked.open.../vavai/riv/strany
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00023841:_____/02:00005571
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - gemcitabine;carboplatin;non-small cell lung cancer (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Investigational New Drugs
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| |
number of pages
| |